

## Assoc. Prof. LEYLA OZER

### Personal Information

Office Phone: [+90 212 404 4553](tel:+902124044553)

Fax Phone: [+90 212 404 4444](tel:+902124044444)

Email: [leyla.ozer@acibadem.edu.tr](mailto:leyla.ozer@acibadem.edu.tr)

Web: <https://avesis.acibadem.edu.tr/11111>

### Education Information

Post Doctorate of Medicine, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, Turkey 2009 - 2013

Expertise In Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 2002 - 2008

Undergraduate, Turkey 1996 - 2002

### Research Areas

Medicine, Health Sciences

### Academic Titles / Tasks

Associate Professor, Acibadem Mehmet Ali Aydinlar University, School of Medicine, Department of Medical Sciences, 2015 - Continues

### Academic and Administrative Experience

İÇ HASTALIKLARI STAJ KOORDİNATÖR YARDIMCILIĞI, Acibadem Mehmet Ali Aydinlar University, School of Medicine, Department of Medical Sciences, 2018 - Continues

Head of Department, Firat University, Faculty Of Medicine, Department Of Internal Medicine, 2014 - 2015

### Courses

SIDE EFFECTS OF CHEMOTHERAPY, Undergraduate, 2019 - 2020

### Jury Memberships

Doctorate, Doctorate, İstanbul Üniversitesi, May, 2019

### Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- Tailored total neoadjuvant therapy for locally advanced rectal cancer: One size may not fit for all!**  
Ozer L., Yıldız İ., Bayoglu V., Bozkurt M., Esen E., Remzi F. H. , Gogenur I., Aytaç E.  
COLORECTAL DISEASE, 2021 (Journal Indexed in SCI)

- II. **The expression levels of miRNA-15a and miRNA-16-1 in circulating tumor cells of patients with diffuse large B-cell lymphoma**  
Tuncer S. B. , Akdeniz D., Celik B., Kilic S., Sukruoglu O., Avsar M., Ozer L., Ekenel M., Ozel S., Yazici H.  
Molecular Biology Reports, vol.46, no.1, pp.975-980, 2019 (Journal Indexed in SCI)
- III. **Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy.**  
Yildiz İ., Bilici A., Karadurmus N., Ozer L., Tural D., Kaplan M. A. , Akman T., Bayoglu I., UYSAL M., Yildiz Y., et al.  
Tumori, vol.104, no.6, pp.444-450, 2018 (Journal Indexed in SCI Expanded)
- IV. **Clinical significance of serum interleukin-17 levels in colorectal cancer patients**  
Karabulut S., Afsar C. U. , Karabulut M., Kilic L., Alis H., Kones O., Bilgin E., Aykan N. F.  
JOURNAL OF BUON, vol.21, no.5, pp.1137-1145, 2016 (Journal Indexed in SCI)
- V. **Current adjuvant treatment modalities for gastric cancer: From history to the future**  
Kilic L., Ordu C., Yildiz İ., Sen F., Keskin S., Ciftci R., Pilanci K. N.  
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol.8, no.5, pp.439-449, 2016 (Journal Indexed in SCI)
- VI. **Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma**  
Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U. , Karanlik H., Kurul S., Vatansever S., Oral E. N. , et al.  
JOURNAL OF DERMATOLOGICAL TREATMENT, vol.27, no.3, pp.275-277, 2016 (Journal Indexed in SCI)
- VII. **Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer**  
Tas F., Yildiz İ., Kilic L., Ciftci R., Keskin S., Sen F.  
AMERICAN JOURNAL OF THERAPEUTICS, vol.23, no.3, 2016 (Journal Indexed in SCI)
- VIII. **Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma**  
Sen F., Yildiz İ., Odabas H., Tambas M., Kilic L., Karadeniz A., Altun M., Ekenel M., Serilmez M., Duranyildiz D., et al.  
TUMOR BIOLOGY, vol.36, no.2, pp.1039-1044, 2015 (Journal Indexed in SCI)
- IX. **D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients**  
Kilic L., Yildiz İ., Sen F. K. , Erdem M. G. , Serilmez M., Keskin S., Ciftci R., Karabulut S., Ordu C., Duranyildiz D., et al.  
CANCER BIOMARKERS, vol.15, no.4, pp.405-411, 2015 (Journal Indexed in SCI)
- X. **Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.**  
Yildiz İ., Varol U., Sen F., Kilic L.  
Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, vol.14, no.7, pp.654-6, 2014 (Journal Indexed in SCI)
- XI. **The behavior of Turkish cancer patients in fasting during the holy month of Ramadan.**  
Tas F., Karabulut S., Ciftci R., Yildiz İ., Keskin S., Kilic L., Disci R.  
Japanese journal of clinical oncology, vol.44, no.8, pp.705-10, 2014 (Journal Indexed in SCI)
- XII. **High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer.**  
Ciftci R., Tas F., Yasasever C. T. , Aksit E., Karabulut S., Sen F., Keskin S., Kilic L., Yildiz İ., Bozbey H. U. , et al.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, no.7, pp.6941-8, 2014 (Journal Indexed in SCI)
- XIII. **Coagulation tests show significant differences in patients with breast cancer.**  
Tas F., Kilic L., Duranyildiz D.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, pp.5985-92, 2014 (Journal Indexed in SCI)
- XIV. **Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.**  
Elitok A., Oz F., Cizgici A., Kilic L., Ciftci R., Sen F., Bugra Z., Mercanoglu F., Oncul A., Oflaz H.  
Cardiology journal, vol.21, pp.509-15, 2014 (Journal Indexed in SCI)
- XV. **Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma.**  
Tas F., Karabulut S., Bilgin E., Kilic L., Ciftci R., Duranyildiz D.

- Journal of gastrointestinal cancer, vol.44, pp.404-9, 2013 (Journal Indexed in SCI Expanded)
- XVI. **Age is a prognostic factor affecting survival in lung cancer patients.**  
Tas F., Ciftci R., Kilic L., Karabulut S.  
Oncology letters, vol.6, pp.1507-1513, 2013 (Journal Indexed in SCI)
- XVII. **Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.**  
Tas F., Sen F., Odabas H., Kilic L., Keskin S., Yildiz İ.  
International journal of clinical oncology, vol.18, no.5, pp.839-46, 2013 (Journal Indexed in SCI)
- XVIII. **Clinical and prognostic significance of coagulation assays in gastric cancer.**  
Tas F., Ciftci R., Kilic L., Serilmez M., Karabulut S., Duranyildiz D.  
Journal of gastrointestinal cancer, vol.44, pp.285-92, 2013 (Journal Indexed in SCI Expanded)
- XIX. **Serum M65 as a biomarker for metastatic renal cell carcinoma.**  
Yildiz İ., Sen F., Kilic L., Keskin S., Duranyildiz D., Bilgin E., Disci R., Ekenel M., Darendeliler E., Bavbek S., et al.  
Clinical genitourinary cancer, vol.11, no.3, pp.290-6, 2013 (Journal Indexed in SCI)
- XX. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer**  
Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.72, no.2, pp.437-444, 2013 (Journal Indexed in SCI)
- XXI. **Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.**  
Keskin S., Tas F., Ekenel M., Kilic L., Sen F., Yildiz İ., Karabulut S., Ciftci R., Vatanserver S.  
Tumori, vol.99, no.4, pp.463-8, 2013 (Journal Indexed in SCI)
- XXII. **Clinical and prognostic significance of coagulation assays in lung cancer.**  
Tas F., Kilic L., Serilmez M., Keskin S., Sen F., Duranyildiz D.  
Respiratory medicine, vol.107, pp.451-7, 2013 (Journal Indexed in SCI)
- XXIII. **Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.**  
Aydiner A., Kilic L., Yildiz İ., Keskin S., Sen F., Kucucuk S., Karanlik H., Muslumanoğlu M., Igci A.  
Medical oncology (Northwood, London, England), vol.30, no.1, pp.354, 2013 (Journal Indexed in SCI)
- XXIV. **Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer.**  
Tas F., Kilic L., Bilgin E., Keskin S., Sen F., Ciftci R., Yildiz İ., Yasasever V.  
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol.23, no.2, pp.276-81, 2013 (Journal Indexed in SCI)
- XXV. **Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer?**  
Aydiner A., Ciftci R., Karabulut S., Kilic L.  
Asian Pacific journal of cancer prevention : APJCP, vol.14, pp.6109-14, 2013 (Journal Indexed in SCI)
- XXVI. **Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.**  
Aykan N. F., Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., Karabulut S., Sakar B., Disci R.  
Medical oncology (Northwood, London, England), vol.30, no.3, pp.679, 2013 (Journal Indexed in SCI)
- XXVII. **Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?**  
Kilic L., Ordu C., Ekenel M., Yildiz İ., Keskin S., Sen F., Gural Z., Asoglu O., Kizir A., Aykan F.  
Medical oncology (Northwood, London, England), vol.30, no.3, pp.660, 2013 (Journal Indexed in SCI)
- XXVIII. **Clinical and prognostic significance of coagulation assays in melanoma.**  
Tas F., Ciftci R., Kilic L., Bilgin E., Keskin S., Sen F., Yildiz İ., Yasasever V.  
Melanoma research, vol.22, no.5, pp.368-75, 2012 (Journal Indexed in SCI)
- XXIX. **The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.**  
Sanli Y., Kuyumcu S., Ozkan Z., Kilic L., Balik E., Turkmen C., Has D., Isik G., Asoglu O., Kapran Y., et al.  
Annals of nuclear medicine, vol.26, pp.551-8, 2012 (Journal Indexed in SCI)

- XXX. **Noncutaneous Melanoma Have Distinct Features from Each Other and Cutaneous Melanoma**  
Tas F., Keskin S., Karadeniz A., Dagoglu N., Sen F., Kilic L., Yildiz İ.  
ONCOLOGY, vol.81, pp.353-358, 2011 (Journal Indexed in SCI)
- XXXI. **Optic disc and choroidal metastasis from sporadic medullary thyroid carcinoma: case report and review of the literature.**  
Yildiz İ., Sen F., Tuncer S., Kilic L., Basaran M., Bavbek S.  
Onkologie, vol.34, no.11, pp.630-3, 2011 (Journal Indexed in SCI)
- XXXII. **The Properties of Vitamin B12 Deficiency in the Patients of an Outpatient Clinic**  
Erden S., Sakar S., Koc Z., Sen F., Cakir H., Gelincik A., Kilic L., Ozdener L.  
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, vol.30, no.6, pp.1845-1851, 2010 (Journal Indexed in SCI)

## Articles Published in Other Journals

- I. **The Youngest Patient with Metastatic Leiomyosarcoma of the Pancreas.**  
Saka D., Şişman G., Özer L., Şahin D., Ceyhan G.  
Journal of gastrointestinal cancer, vol.51, pp.722-723, 2020 (Refereed Journals of Other Institutions)
- II. **Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk extremity soft tissue sarcoma: a single-institution experience.**  
Kılıç L., Ekenel M., Karabulut S., Ağaoğlu F., Darendeliler E.  
Contemporary oncology (Poznan, Poland), vol.21, pp.60-65, 2017 (Journal Indexed in ESCI)
- III. **Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.**  
Karabulut S., Afsar Ç., Karabulut M., Alış H., Kılıç L., Çikot M., Yasasever C., Aykan N.  
Journal of gastrointestinal cancer, vol.47, pp.47-54, 2016 (Journal Indexed in ESCI)
- IV. **The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience.**  
Eralp Y., Kılıç L., Alço G., Başaran G., Doğan M., Dinçol D., Demirci S., İçli F., Onur H., Saip P., et al.  
The journal of breast health, vol.10, pp.209-215, 2014 (Journal Indexed in ESCI)
- V. **Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.**  
Yildiz İ., Sen F., Kilic L., Ciftci R., BAŞARAN M.  
Korean journal of urology, vol.55, no.1, pp.74-6, 2014 (Journal Indexed in ESCI)
- VI. **Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival.**  
Tas F., Sen F., Keskin S., Kilic L., Yildiz İ.  
Molecular and clinical oncology, vol.1, pp.788-792, 2013 (Journal Indexed in ESCI)

## Books & Book Chapters

- I. **Hematopoetik Tedaviler**  
Ozer L.  
in: ONKOLOJİ HEMŞİRELİĞİ, gülbeyaz can, Editor, Nobel Yayın Dağıtım, İstanbul, pp.655-666, 2020
- II. **ADJUVANT CHEMOTHERAPY FOR HER2-NEGATIVE EARLY STAGE BREAST CANCER**  
Ozer L.  
in: BREAST CANCER - A GUIDE TO CLINICAL PRACTICE , ADNAN AYDINER, ATILLA SORAN, ABDULLAH IGCI, Editor, Springer, London/Berlin , Geneve, pp.357-383, 2019

## Refereed Congress / Symposium Publications in Proceedings

- I. **Factors affecting progression free survival in non-HIV related classical Kaposi sarcoma.**  
Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U. , Karanlik H., Kurul S., Vatansever S., Saip P., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- II. **OUTCOME OF BRAIN METASTASES FROM COLORECTAL CANCER; A SINGLE INSTITUTE EXPERIENCE**  
Ekenel M., Kilic L., Aykan F. N.  
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.224

## **Scientific Refereeing**

journal of oncological Sciences , Other journals, May 2020

## **Citations**

Total Citations (WOS):410

h-index (WOS):12